drugset / Trial / NCT00148928
Safety & Activity of P501-AS15 Vaccine as a First-line Treatment for Patients With Hormone-sensitive Prostate Cancer Who Show Rising PSA
Non-randomizedSingle-groupOpen-labelPrevention
Summary
Patients with hormone-sensitive prostate cancer and rising PSA, after primary tumor treatment, will be treated with the P501-AS15 vaccine as out-patients. The maximum dose will be 16 vaccinations, given over a period of approximately one year. Thereafter, the patients' long-term safety and PSA status will be followed over a period of approximately 11 months.
Timeline
- Start
- 2005-03-01
- Primary completion
- 2006-11-07
- Completion
- 2006-11-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | P501-AS15 | Vaccine | — | — |